PASADENA, Calif. --(BUSINESS WIRE)--Jan. 25, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for a Phase 2b dose-finding clinical study of ARO-ANG3, the company’s

PASADENA, Calif. --(BUSINESS WIRE)--Jan. 19, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 4, 2021 , at 4:30 p.m. EST to discuss its financial results for the fiscal first quarter ended December 31, 2020 .

PASADENA, Calif. --(BUSINESS WIRE)--Dec. 7, 2020-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 4, 2020 , the Compensation Committee of the Board of Directors approved “inducement” grants to 27 new

PASADENA, Calif. --(BUSINESS WIRE)--Nov. 30, 2020-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Piper Sandler 32 nd Annual Virtual Healthcare Conference – December 1-3, 2020 December 2, 2020 –   Chris Anzalone

PASADENA, Calif. --(BUSINESS WIRE)--Nov. 25, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the collaboration and license agreement between Arrowhead and Takeda Pharmaceutical Company Limited announced on October 8, 2020 , has now closed.

- Conference Call and Webcast Today, November 23 at 4:30 p.m. EST PASADENA, Calif. --(BUSINESS WIRE)--Nov. 23, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2020 . The company is hosting a conference call at 4:30 p.m.

- ARO-APOC3 achieved triglyceride reductions of 74-92% - ARO-ANG3 achieved triglyceride reductions of 29-75% and LCL-C reductions of 29-35% - Company to host upcoming KOL webinars on ARO-APOC3 and ARO-ANG3 PASADENA, Calif. --(BUSINESS WIRE)--Nov. 13, 2020-- Arrowhead Pharmaceuticals, Inc.

- Serum Z-AAT reductions of 86-93% - All patients demonstrated greater than 80% reduction in liver Z-AAT monomer - 3 of 4 patients had a decrease in liver globule involvement - 3 of 4 patients demonstrated reductions in Z-AAT polymer with a range of 68-97% - All patients showed ALT reductions

PASADENA, Calif. --(BUSINESS WIRE)--Nov. 9, 2020-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: The Liver Meeting Digital Experience, the Annual Meeting of the American Association for the Study of Liver Disease

PASADENA, Calif. --(BUSINESS WIRE)--Nov. 4, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on November 18 , and November 19, 2020 , it will host two key opinion leader (KOL) webinars to discuss the company’s two investigational RNA interference (RNAi) based